Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Phenolphthalein meeting

This article was originally published in The Tan Sheet

Executive Summary

Phenolphthalein meeting: OTC "feedback" meeting between FDA and Novartis on phenolphthalein scheduled for Dec. 11. In comments filed last June in anticipation of the agency's proposed ban of the ingredient, Novartis proposed a case-control human surveillance study to better assess whether the use of phenolphthalein-containing laxatives are cause for safety concern ("The Tan Sheet" June 23, p. 9). The company also submitted a report by CanTox consultants that reviewed both new and existing National Toxicology Program data on the ingredient. FDA's proposal was published in September; Novartis responded to the proposed ban by reformulating Ex-Lax with senna ("The Tan Sheet" Sept. 1, p. 1). The feedback meeting will begin at 3:30 p.m. in Room 200A of FDA's Rockville, Md. offices at 9201 Corporate Boulevard...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel